霍奇金淋巴瘤:2020年诊断、风险分层与管理更新
霍奇金淋巴瘤(HL)是罕见的B细胞淋巴系统恶性肿瘤,美国每年新增8480例,约占所有淋巴瘤的10%。诊断分经典型HL和结节性淋巴细胞为主型HL,经典型含四个亚型;治疗依据组织学、解剖分期和不良预后特征制定风险适应策略,早期用联合模式治疗,晚期用较长程化疗,复发难治者以自体干细胞移植为标椎。
要点
- HL分经典型和结节性淋巴细胞为主型,经典型含结节硬化型、混合细胞型、淋巴细胞消减型和淋巴细胞丰富型四个亚型。
- 准确分期是选择合适治疗的关键,预后模型和PET扫描确定的治疗反应用于优化治疗。
- 复发难治患者以高剂量化疗联合自体干细胞移植为标准治疗,失败后可考虑维布妥昔单抗、PD-1阻断、非清髓性异基因移植或临床试验。
核心结论
- HL的治疗基于疾病组织学、解剖分期和不良预后特征制定风险适应策略;早期患者通常采用联合模式治疗,晚期患者接受较长程化疗,常不含放疗;新型药物维布妥昔单抗和抗PD-1抗体正被纳入一线治疗。
研究设计与样本
- 本文为综述,未报告检索范围与样本量。
主要发现
- HL在美国每年新增8480例,约占所有淋巴瘤的10%。
- HL分为经典型HL和结节性淋巴细胞为主型HL两个不同疾病实体。
- 经典型HL的亚组包括结节硬化型、混合细胞型、淋巴细胞消减型和淋巴细胞丰富型。
- 复发难治患者中,高剂量化疗后自体干细胞移植是大多数初始治疗后复发患者的标准治疗。
- 对高剂量化疗联合自体干细胞移植失败的患者,应考虑维布妥昔单抗、PD-1阻断、非清髓性异基因移植或参加临床试验。
关键数值与推荐
- 早期 stage 疾病患者通常接受联合模式策略,包括缩短疗程的联合化疗后行累及野放疗。
- 晚期 stage 疾病患者接受较长疗程化疗,通常不含放疗。
- 复发后大多数患者的标准治疗为高剂量化疗后行自体干细胞移植。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually and representing approximately 10% of all lymphomas in the United States. DIAGNOSIS: Hodgkin lymphoma is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL. RISK STRATIFICATION: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography (PET) scan, are used to optimize therapy. RISK-ADAPTED THERAPY: Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy, followed by involved-field radiation therapy. Patients with advanced stage disease receive a longer course of chemotherapy, often without radiation therapy. However, newer agents including brentuximab vedotin and anti-PD-1 antibodies are now being incorporated into frontline therapy. MANAGEMENT OF RELAPSED/REFRACTORY DISEASE: High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant or participation in a clinical trial should be considered.
引用
- Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020. PMID: 32384177. doi:10.1002/ajh.25856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。